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Background: First identiﬁed in 2012, Middle East respiratory
syndrome (MERS) is caused by an emerging human coronavirus,
which is distinct from SARS-CoV, and represents a novel member
of lineage C betacoronoviruses. Since its identiﬁcation, MERS-CoV
has been linked to over 964 infections manifesting with severe
morbidity and often mortality (i.e. approximately 400+ deaths) in
the Arabian Peninsula, Europe, in the US and in Korea. Human-
to-human transmission has been documented with nosocomial
transmission appearing to be an important route of infection. The
signiﬁcant recent increase in cases ofMERS in theMiddle East, cou-
pledwith the lack of effective antiviral therapies or vaccines to treat
or prevent this infection are signiﬁcant causes for concern.
Methods & Materials: A synthetic DNA plasmid based vac-
cine containing a full-length consensus MERS-S protein sequence
was constructed and the cellular and humoral immunogenicity
of MERS-vaccine was evaluated in mice, macaues, and camels.
Following immunization, NHPs were challenged with infectious
MERS-CoV (EMC/2012) andmonitored for signs of infection by clin-
ical scoring and examinations. Viral loadwasmeasured by qRT-PCR
and tissue sections were stained with H&E.
Results: An optimized DNA vaccine encoding the MERS spike
protein induced potent cellular immunity and antigen speciﬁc neu-
tralizing antibodies in mice, macaques and camels. Vaccinated
rhesus macaque monkeys seroconverted rapidly and exhibited
high levels of virus-neutralizing activity. Upon MERS viral chal-
lenge all of themonkeys in the control-vaccinated group developed
characteristic disease, including pneumonia. Vaccinated macaques
were protected and failed to demonstrate any clinical or radio-
graphic signs of pneumonia.
Conclusion: A consensus DNA MERS-vaccine was able to gen-
erate both a strong T cell and neutralizing antibody response in
multiple animalmodels, including camels, a natural host forMERS-
CoV and a probable source of human infection. MERS-vaccine was
also able to protect NHPs from an infectious MERS-CoV challenge.
These results demonstrate the promise of this consensus DNA
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Climate change and disease dynamics - A big
data perspective
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Background: The objective of this research is to predict dis-
ease scenarios based on environmental conditions change and
climatic variability by combining regional climate models with
mathematicalmodels for disease transmission.Malaria anddengue
fever are the most important vector borne diseases in the trop-
ical and sub-tropicalcountries. Integration of large repositories
of geospatial and health data derived from traditional stream as
vital statistics, surveillanceandhospitalization, andnon-traditional
sources including social media networks provide valuable
insights into the spatio-temporal determinants of health and
wellbeing.
Methods & Materials: Data on infectious affected by vector
borne diseases (Malaria) are collected from various private and
public health centres, for the period starting January 1998 to
December 2013 in Tamil Nadu, India. Daily weather data is col-
lected from Regional Meteorological Centre, Chennai (Figure 1).
The suggested approach is implemented as a Big Data system using
lambda architecture and MapReduce data processing model (Fig-
ure 2). Pearson correlation coefﬁcient is computed in the proposed
framework to ﬁnd the climatic factors that greatly inﬂuence the
transmission of the vector borne diseases.
Results: This paper proposes a new architecture for modeling
the climate change and vector borne diseases in real-time. A variety
of big data analytical algorithms and data visualization approaches
were used in the proposed big data based disease surveillance
system to present the geographic regions at risk during this cen-
tury.We found thatmaximum temperature is positively correlated
while incidences of malaria and minimum temperature, wind,
